Efficacy and safety of a 4-week course of repeated subcutaneous ketamine injections for treatment-resistant depression (KADS study): Randomised double-blind active-controlled trial: Commentary, author response

Colleen Loo; Angelo Alonzo; David Barton; Michael Berk; Mary Lou Chatterton; Vanessa Dong; Veronica Gálvez; Natalie T. Mills; Philip B. Mitchell; Shanthi Sarma; Andrew A. Somogyi; Anthony Rodgers

doi:10.1192/bjp.2024.176

Efficacy and safety of a 4-week course of repeated subcutaneous ketamine injections for treatment-resistant depression (KADS study): Randomised double-blind active-controlled trial: Commentary, author response

Colleen Loo
, Angelo Alonzo
, David Barton
, Michael Berk
, Mary Lou Chatterton
, Vanessa Dong
, Veronica Gálvez
, Natalie T. Mills
, Philip B. Mitchell
, Shanthi Sarma
, Andrew A. Somogyi
, Anthony Rodgers

Research output: Contribution to journal › Comment / Debate › Other › peer-review

Original language	English
Pages (from-to)	317-318
Number of pages	2
Journal	British Journal of Psychiatry
Volume	226
Issue number	5
DOIs	https://doi.org/10.1192/bjp.2024.176
Publication status	Published - 1 May 2025

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Keywords

affective disorders
clinical drug studies
Ketamine/esketamine
major depressive disorder
neuroscience

Access to Document

10.1192/bjp.2024.176

Cite this

Loo, C., Alonzo, A., Barton, D., Berk, M., Chatterton, M. L., Dong, V., Gálvez, V., Mills, N. T., Mitchell, P. B., Sarma, S., Somogyi, A. A., & Rodgers, A. (2025). Efficacy and safety of a 4-week course of repeated subcutaneous ketamine injections for treatment-resistant depression (KADS study): Randomised double-blind active-controlled trial: Commentary, author response. British Journal of Psychiatry, 226(5), 317-318. https://doi.org/10.1192/bjp.2024.176

@article{8e946eadb3a94ab79af396d74430d6c2,

title = "Efficacy and safety of a 4-week course of repeated subcutaneous ketamine injections for treatment-resistant depression (KADS study): Randomised double-blind active-controlled trial: Commentary, author response",

keywords = "affective disorders, clinical drug studies, Ketamine/esketamine, major depressive disorder, neuroscience",

author = "Colleen Loo and Angelo Alonzo and David Barton and Michael Berk and Chatterton, \{Mary Lou\} and Vanessa Dong and Veronica G{\'a}lvez and Mills, \{Natalie T.\} and Mitchell, \{Philip B.\} and Shanthi Sarma and Somogyi, \{Andrew A.\} and Anthony Rodgers",

year = "2025",

month = may,

day = "1",

doi = "10.1192/bjp.2024.176",

language = "English",

volume = "226",

pages = "317--318",

journal = "British Journal of Psychiatry",

issn = "0007-1250",

publisher = "Cambridge University Press",

number = "5",

}

Loo, C, Alonzo, A, Barton, D, Berk, M, Chatterton, ML, Dong, V, Gálvez, V, Mills, NT, Mitchell, PB, Sarma, S, Somogyi, AA & Rodgers, A 2025, 'Efficacy and safety of a 4-week course of repeated subcutaneous ketamine injections for treatment-resistant depression (KADS study): Randomised double-blind active-controlled trial: Commentary, author response', British Journal of Psychiatry, vol. 226, no. 5, pp. 317-318. https://doi.org/10.1192/bjp.2024.176

Efficacy and safety of a 4-week course of repeated subcutaneous ketamine injections for treatment-resistant depression (KADS study): Randomised double-blind active-controlled trial: Commentary, author response. / Loo, Colleen; Alonzo, Angelo; Barton, David et al.
In: British Journal of Psychiatry, Vol. 226, No. 5, 01.05.2025, p. 317-318.

Research output: Contribution to journal › Comment / Debate › Other › peer-review

TY - JOUR

T1 - Efficacy and safety of a 4-week course of repeated subcutaneous ketamine injections for treatment-resistant depression (KADS study)

T2 - Randomised double-blind active-controlled trial: Commentary, author response

AU - Loo, Colleen

AU - Alonzo, Angelo

AU - Barton, David

AU - Berk, Michael

AU - Chatterton, Mary Lou

AU - Dong, Vanessa

AU - Gálvez, Veronica

AU - Mills, Natalie T.

AU - Mitchell, Philip B.

AU - Sarma, Shanthi

AU - Somogyi, Andrew A.

AU - Rodgers, Anthony

PY - 2025/5/1

Y1 - 2025/5/1

KW - affective disorders

KW - clinical drug studies

KW - Ketamine/esketamine

KW - major depressive disorder

KW - neuroscience

UR - https://www.scopus.com/pages/publications/105006755712

U2 - 10.1192/bjp.2024.176

DO - 10.1192/bjp.2024.176

M3 - Comment / Debate

AN - SCOPUS:105006755712

SN - 0007-1250

VL - 226

SP - 317

EP - 318

JO - British Journal of Psychiatry

JF - British Journal of Psychiatry

IS - 5

ER -

Efficacy and safety of a 4-week course of repeated subcutaneous ketamine injections for treatment-resistant depression (KADS study): Randomised double-blind active-controlled trial: Commentary, author response

UN SDGs

Keywords

Access to Document

Other files and links

Ketamine therapy among patients with treatment-resistant depression: a randomsied, double-blind, placebo-controlled trial

Cite this

Efficacy and safety of a 4-week course of repeated subcutaneous ketamine injections for treatment-resistant depression (KADS study): Randomised double-blind active-controlled trial: Commentary, author response

UN SDGs

Keywords

Access to Document

Other files and links

Projects

Ketamine therapy among patients with treatment-resistant depression: a randomsied, double-blind, placebo-controlled trial

Cite this